Management of children and adolescents with primary immune thrombocytopenia: Controversies and solutions

Vox Sanguinis

Volumn 104, Issue 1, 2013, Pages 55-66

  Kuhne T ^a   Imbach, P ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Immune thrombocytopenia; Management; Paediatrics; Platelets; Registry

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; ELTROMBOPAG; IMMUNOGLOBULIN; PREDNISONE; RHESUS D ANTIBODY; RITUXIMAB; ROMIPLOSTIM;

ABDOMINAL PAIN; ADOLESCENT; ARTHRALGIA; ASEPTIC MENINGITIS; BEHAVIOR CHANGE; BLEEDING; CHILD; CHILL; CLINICAL FEATURE; DIARRHEA; DIZZINESS; DRUG TOLERABILITY; ECONOMIC ASPECT; FATIGUE; FEVER; HEADACHE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTRAVASCULAR HEMOLYSIS; MYELOFIBROSIS; NAUSEA; PAIN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SORE THROAT; SPLENECTOMY; STOMACH PAIN; THROMBOCYTE COUNT; THROMBOEMBOLISM; VOMITING;

ADOLESCENT; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; DISEASE MANAGEMENT; FEMALE; HEMATOLOGY; HUMANS; INFANT; MALE; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; QUALITY OF LIFE; REGISTRIES; RISK; TREATMENT OUTCOME;

EID: 84871272809     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2012.01636.x     Document Type: Review

References (98)

1. Blanchette V, Bolton-Maggs P: Childhood immune thrombocytopenic purpura: diagnosis and management. Hematol Oncol Clin North Am 2010; 24:249-273.
2. Kühne T: Immune Thrombocytopenia (ITP), 1st edn. Bremen, UNI-MED, 2010.
3. De Mattia D, Del Vecchio GC, Russo G, et al.: AIEOP-ITP Study Group. Management of chronic childhood immune thrombocytopenic purpura: AIEOP consensus guidelines. Acta Haematol 2010; 123:96-109.
4. Bennett CM, Tarantino M: Chronic immune thrombocytopenia in children: epidemiology and clinical presentation. Hematol Oncol Clin North Am 2009; 23:1223-1238.
5. Segel GB, Feig SA: Controversies in the diagnosis and management of childhood acute immune thrombocytopenic purpura. Pediatr Blood Cancer 2009; 53:318-324.
6. Blanchette V, Bolton-Maggs P: Childhood immune thrombocytopenic purpura: diagnosis and management. Pediatr Clin North Am 2008; 55:393-420.
7. Kalpatthi R, Bussel JB: Diagnosis, pathophysiology and management of children with refractory immune thrombocytopenic purpura. Curr Opin Pediatr 2008; 20:8-16.
8. Schoonen WM, Kucera G, Coalson J, et al.: Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol 2009; 145:235-244.
9. Panzer S: Platelet function in immune thrombocytopenia; in Kühne T (ed.): Immune Thrombocytopenia (ITP), 1st edn. Bremen, UNI-MED, 2010:38-42.
10. Semple JW, Italiano JE Jr, Freedman J: Platelets and the immune continuum. Nat Rev Immunol 2011; 11:264-274.
11. Tsubakio T, Tani P, Curd JG, et al.: Complement activation in vitro by antiplatelet antibodies in chronic immune thrombocytopenic purpura. Br J Haematol 1986; 63:293-300.
12. Wentworth P Jr, Jones LH, Wentworth AD, et al.: Antibody catalysis of the oxidation of water. Science 2001; 293:1806-1811.
13. Rischewski JR, Imbach P, Paulussen M, et al.: Idiopathic thrombocytopenic purpura (ITP): is there a genetic predisposition?Pediatr Blood Cancer 2006; 5(Suppl):678-680.
14. Bergmann AK, Grace RF, Neufeld EJ: Genetic studies in pediatric ITP: outlook, feasibility, and requirements. Ann Hematol 2010; 89(Suppl 1):S95-S103.
15. Cines DB, Blanchette VS: Immune thrombocytopenic purpura. N Engl J Med 2002; 346:995-1008.
16. Toltl LJ, Arnold DM: Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters. Br J Haematol 2010; 152:52-60.
17. Semple JW, Provan D, Garvey MB, et al.: Recent progress in understanding the pathogenesis of immune thrombocytopenia. Curr Opin Hematol 2010; 17:590-595.
18. Imbach P, Lazarus AH, Kühne T: Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders. Vox Sang 2010; 98:385-394.
19. Rodeghiero F, Stasi R, Gernsheimer T, et al.: Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children. Report from an international working group. Blood 2009; 113:2386-2393.
20. Provan D, Stasi R, Newland AC, et al.: International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115:168-186.
21. Neunert C, Lim W, Crowther M, et al.: The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117:4190-4207.
22. Kühne T, Imbach P, Bolton-Maggs PHB, et al.: Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet 2001; 358:2122-2125.
23. Kühne T, Buchanan GR, Zimmerman S, et al.: A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from The Intercontinental Childhood ITP Study Group. J Pediatr 2003; 143:605-608.
24. Neunert CE, Buchanan GR, Imbach P, et al.: Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 2008; 112:4003-4008.
25. Kühne T, Blanchette V, Buchanan GR, et al.: Splenectomy in children with idiopathic thrombocytopenic purpura: a prospective study of 134 children from the Intercontinental Childhood ITP Study Group. Pediatr Blood Cancer 2007; 49:829-834.
26. Kühne T, Berchtold W, Michaels LA, et al.: Newly diagnosed immune thrombocytopenia in children and adults, a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica 2011; 96:1831-1837.
27. Bolton-Maggs PH: Severe bleeding in idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003; 25:S47-S51.
28. Buchanan GR, Adix L: Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr 2002; 141:683-688.
29. Wendtland EP, Rosthøj S, Treutiger I, et al.: A clinical score predicting a brief and uneventful course of newly diagnosed idiopathic trombocytopenic purpura in children. Br J Hematol 2007; 138:513-516.
30. Drachman JG: Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004; 103:390-398.
31. Cines DB, Bussel JB, Liebman HA, et al.: The ITP syndrome: pathogenic and clinical diversity. Blood 2009; 113:6511-6521.
32. Kaznelson P: Verschwinden der hämorrhagischen Diathese bei einem Falle von essentieller Thrombopenie (Frank) nach Milzexstirpation. Wien Klin Wschr 1916; 29:1451-1454.
33. Kojouri K, Vesely SK, Terrell DR, et al.: Splenecotomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104:2623-2634.
34. Wintrobe MM, Cartwright GE, Palmer JG, et al.: Effect of corticotrophin and cortisone on the blood in various disorders in man. Arch Intern Med 1951; 88:310-336.
35. Imbach P, d'Appuzzo V, Hirt A, et al.: High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1:1228-1231.
36. Salama A, Kiefel V, Amberg R, et al.: Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D). Blut 1984; 49:29-35.
37. Bolton-Maggs PH, Moon I: Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet 1997; 350:620-623.
38. Zeller B, Helgestad J, Hellebostad M, et al.: Immune thrombocytopenic purpura in childhood in Norway: a prospective, population-based registration. Pediatr Hematol Oncol 2000; 17:551-558.
39. Sutor AH, Harms A, Kaufmehl K: Acute immune thrombocytopenia (ITP) in childhood: retrospective and prospective survey in Germany. Semin Thromb Hemost 2001; 27:253-267.
40. Lilleyman JS: Intracranial haemorrhage in idiopathic thrombocytopenic purpura: paediatric idiopathic thrombocytopenic purpura. Paediatric Haematology Forum of the British Society for Haematology. Arch Dis Child 1994; 71:251-253.
41. Butros LJ, Bussel JB: Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis. J Pediatr Hematol Oncol 2003; 25:660-664.
42. Lilleyman JS: Intracranial hemorrhage in chronic childhood ITP. Pediatr Hematol Oncol 1997; 14:III-V.
43. Psaila B, Petrovic A, Page LK, et al.: Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood 2009; 114:4777-4783.
44. British Committee for Standards in Haematology General Haematology Task Force: Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120:574-596.
45. Imbach P, Kühne T, Müller D, et al.: Childhood ITP: 12months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer 2006; 46:351-356.
46. Sartorius JA: Steroid treatment of idiopathic thrombocytopenic purpura in children. Preliminary results of a randomized cooperative study. Am J Pediatr Hematol Oncol 1984; 6:165-169.
47. Buchanan GR, Holtkamp CA: Prednisone therapy for children with newly diagnosed idiopathic thrombocytopenic purpura. A randomized clinical trial. Am J Pediatr Hematol Oncol 1984; 6:355-361.
48. Carcao MD, Zipursky A, Butchart S, et al.: Short-course oral prednisone therapy in children presenting with acute immune thrombocytopenic purpura (ITP). Acta Paediatr Suppl 1998; 424:71-74.
49. van Hoff J, Ritchey AK: Pulse methylprednisolone therapy for acute childhood idiopathic thrombocytopenic purpura. J Pediatr 1988; 113:563-566.
50. Özsoylu S, Sayli TR, Öztürk G: Oral megadose methylprednisolone versus intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 1993; 10:317-321.
51. Mazzucconi MG, Fazi P, Bernasconi S, et al.: Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007; 109:1401-1407.
52. Kühne T, Freedman J, Semple JW, et al.: Platelet and immune responses to oral cyclic dexamethasone in childhood chronic immune thrombocytopenic purpura. J Pediatr 1997; 130:17-24.
53. Lazarus A: Adoptive-transfer effects of intravenous immunoglobulin in autoimmunity. J Clin Immunol 2010; 30(Suppl 1):S20-S30.
54. Imbach P, Wagner HP, Berchtold W, et al.: Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 1985; 2:464-468.
55. Godeau B, Caulier MT, Decuypere L, et al.: Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1g/kg b.w. Br J Haematol 1999; 107:716-719.
56. Qin YH, Zhou TB, Su LN, et al.: The efficacy of different dose intravenous immunoglobulin in treating acute idiopathic thrombocytopenic purpura: a meta-analysis of 13 randomized controlled trials. Blood Coagul Fibrinolysis 2010; 21:713-721.
57. Blanchette V, Imbach P, Andrew M, et al.: Randomised trial of intravenous immunoglobulin G, intravenous anti-D and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994; 344:703-707.
58. Blanchette VS, Luke B, Andrew M, et al.: A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 1993; 123:989-995.
59. Caress JB, Kennedy BL, Eickman KD: Safety of intravenous immunoglobulin treatment. Expert Opin Drug Saf 2010; 9:971-979.
60. Salama A, Mueller-Eckhardt C, Kiefel V: Effect of intravenous immunoglobulin in immune thrombocytopenia. Competitive inhibition of reticuloendothelial system function by sequestration of autologous red blood cells?Lancet 1983; 2:193-195.
61. Salama A, Kiefel V, Mueller-Eckhart C: Effect of IgG anti-Rho(D) in adult patients with chronic autoimmune thrombocytopenia. Am J Hematol 1986; 22:241-250.
62. Scaradavou A, Woo B, Woloski BMR, et al.: Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997; 89:2689-2700.
63. Crow AR, Lazarus AH: The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?Transfus Med Rev 2008; 22:103-116.
64. Andrew M, Blanchette VS, Adams M, et al.: A multicenter study of the treatment of childhood chronic idiopathic thrombocytopenic purpura with anti-D. J Pediatr 1992; 120:522-527.
65. Tarantino MD, Young G, Bertolone SJ, et al.: Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr 2006; 148:489-494.
66. Meyer O, Kiesewetter H, Hermsen M, et al.: Efficacy and safety of anti-D given by subcutaneous injection to patients with autoimmune thrombocytopenia. Eur J Haematol 2004; 73:71-72.
67. Kjaersgaard M, Wendtland Edslev P, Hasle H: Subcutaneous anti-d treatment of idiopathic thrombocytopenic purpura in children. Pediatr Blood Cancer 2009; 53:1315-1317.
68. Gaines AR: Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood 2000; 95:2523-2529.
69. Gaines AR: Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005; 106:1532-1537.
70. Branehög I, Kutti J, Weinfeld A: Platelet survival and platelet production in diopathic thrombocytopenic purpura (ITP). Br J Haematol 1974; 27:127-143.
71. Ballem PJ, Segal GM, Stratton JR, et al.: Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987; 80:33-40.
72. Chang M, Nakagawa PA, Williams SA, et al.: Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003; 102:887-895.
73. Nichol JL: Endogenous TPO (eTPO) levels in health and disease: possible clues for therapeutic intervention. Stem Cells 1998; 16(Suppl 2):165-175.
74. Aledort LM, Hayward CP, Chen MG, et al.: Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004; 76:205-213.
75. Li J, Yang C, Xia Y, et al.: Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98:3241-3248.
76. Kuter DJ: New thrombopoietic growth factors. Blood 2007; 109:4607-4616.
77. Imbach P, Crowther M: Thrombopoietin-receptor agonists for primary immeune thrombocytopenia. N Engl J Med 2011; 365:734-741.
78. Newland A: Thrombopoietin receptor agonists in the treatment of thrombocytopenia. Curr Opin Hematol 2009; 16:357-364.
79. Stasi R, Bosworth J, Rhodes E, et al.: Thrombopoietic agents. Blood Rev 2010; 24:179-190.
80. Khellaf M, Michel M, Quittet P, et al.: Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood 2011; 118:4338-4345.
81. Bussel JB, Provan D, Shamsi T, et al.: Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373:641-648.
82. Bredlau AL, Semple JW, Segel GB: Management of immune thrombocytopenic purpura in children: potential role of novel agents. Paediatr Drugs 2011; 13:213-223.
83. Bussel JB, Buchanan GR, Nugent DJ, et al.: A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 2011; 118:28-36.
84. Klaassen RJ, Mathias SD, Buchanan G, et al.: Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). Pediatr Blood Cancer 2012; 58:395-398.
85. Elalfy MS, Abdelmaksoud AA, Eltonbary KY: Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. Ann Hematol 2011; 90:1341-1344.
86. Stasi R, Del Poeta G, Stipa E, et al.: Response to B-cell depleting therapy with rituximab reverts the abnormalities of T cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007; 110:2924-2930.
87. Stasi R, Cooper N, Del Poeta G, et al.: Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008; 112:1147-1150.
88. Arnold DM, Dentali F, Crowther MA, et al.: Systematic review: efficacy and safety of rituximab for adults with idopathic thrombocytopenic purpura. Ann Intern Med 2007; 146:25-33.
89. Bennett CM, Rogers ZR, Kinnamon DD, et al.: Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006; 107:2639-2642.
90. Parodi E, Rivetti E, Amendola G, et al.: Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response. Br J Haematol 2009; 144:552-558.
91. Neunert CE, Bright BC, Buchanan GR: Severe chronic refractory immune thrombocytopenic purpura during childhood: a survey of physician management. Pediatr Blood Cancer 2008; 51:513-516.
92. Grace RF, Bennett CM, Ritchey AK, et al.: Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatr Blood Cancer 2012; 58:221-225.
93. Zaja F, Baccarani M, Mazza P, et al.: Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010; 115:2755-2762.
94. Carson KR, Evens AM, Richey EA, et al.: Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834-4840.
95. Arnold DM, Bernotas A, Nazi I, et al.: Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica 2009; 94:850-856.
96. Aronis S, Platokouki H, Avgeri M, et al.: Retrospective evaluation of long-term efficacy and safety of splenectomy in chronic idiopathic thrombocytopenic purpura in children. Acta Paediatr 2004; 93:638-642.
97. Roca M, Muñiz-Diaz E, Mora J, et al.: The scintigraphic index spleen/liver at 30minutes predicts the success of splenectomy in persistent and chronic primary immune thrombocytopenia. Am J Hematol 2011; 86:909-913.
98. Najean Y, Rain JD, Billotey C: The site of destruction of autologous 111In-labelled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 578 patients with 268 splenectomies. Br J Haematol 1997; 97:547-550.